At the end of a recent FDA advisory committee meeting dealing with the thorny issue of how to design a complicated new study for an approved therapy in a new indication, a senior FDA official was overheard saying: “If you need someone to talk about clinical trials, he’s the guy.”
The person in question is statistician Thomas Fleming (University of Washington) and the trial design under review was for
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?